Table 1.
Demographics, characteristics, and interventions of eyes with visual impairment from center-involved diabetic macular edema stratified by visual acuity response at one year following treatments
| Characteristics | Overall (N = 226 Eyes) | Gain ≥ 10 Letters at 1 Year (N = 110 Eyes) | Gain < 10 Letters at 1 Year (N = 116 Eyes) | P Value* |
|---|---|---|---|---|
| Demographics | ||||
| Age ≥ 60 years, n (%) | 78 (34.5) | 30 (27.3) | 48 (41.4) | 0.041 |
| Male, n (%) | 122 (54) | 66 (60) | 56 (48.3) | 0.112 |
| Severe NPDR to PDR stage, n (%) | 158 (69.9) | 75 (68.2) | 83 (71.6) | 0.638 |
| Previous macular laser photocoagulation, n (%) | 42 (18.6) | 13 (11.8) | 29 (25) | 0.019 |
| Previous PRP, n (%) | 63 (27.9) | 28 (25.5) | 35 (30.2) | 0.528 |
| Phakia, n (%) | 202 (89.4) | 102 (92.7) | 100 (86.2) | 0.115 |
| Ocular characteristics at baseline | ||||
| Mean (SD) VA, letter | 51.8 (19.1) | 46 (21) | 57.3 (15.2) | < 0.001 |
| VA ≥ 69 letters, n (%) | 63 (27.9) | 23 (20.9) | 40 (34.5) | 0.025 |
| Mean CSFT (SD), µm | 496.2 (145.2) | 513.9 (164.5) | 479.4 (122.6) | 0.159 |
| CSFT ≥ 400 µm | 163 (72.1) | 80 (72.3) | 83 (81.6) | 0.983 |
| ERM, n (%) | 28 (12.4) | 7 (6.4) | 21 (18.1) | 0.012 |
| DRIL, n (%) | 65 (28.8) | 24 (21.8) | 41 (35.3) | 0.026 |
| HF, n (%) | 99 (43.8) | 52 (47.3) | 47 (40.5) | 0.257 |
| IRC ≥ 600 µm, n (%) | 23 (10.2) | 9 (8.2) | 14 (12.1) | 0.399 |
| Disruption of ELM, n (%) | 61 (26.9) | 30 (27.3) | 31 (26.7) | 0.858 |
| Disruption of EZ, n (%) | 56 (24.8) | 18 (16.4) | 38 (32.8) | 0.003 |
| SRF, n (%) | 113 (50) | 59 (53.6) | 54 (46.6) | 0.316 |
| Foveal exudate, n (%) | 15 (6.6) | 6 (5.5) | 9 (7.8) | 0.507 |
| Ocular characteristics at week 12 | ||||
| Mean (SD) VA, letter | 61.7 (17.8) | 63.6 (17.8) | 59.9 (17.7) | 0.172 |
| VA gain < 5 letters, n (%) | 80 (35.4) | 13 (11.8) | 67 (57.8) | < 0.001 |
| CSFT reduction < 10%, n (%) | 78 (34.5) | 27 (24.6) | 51 (44.0) | 0.004 |
| DRIL, n (%) | 42 (18.6) | 13 (11.8) | 29 (25) | 0.012 |
| HF, n (%) | 63 (27.9) | 31 (28.2) | 32 (27.6) | 0.812 |
| IRC ≥ 600 µm, n (%) | 15 (6.6) | 4 (3.6) | 11 (9.5) | 0.046 |
| Disruption of ELM, n (%) | 43 (19) | 12 (10.9) | 31 (26.7) | 0.002 |
| Disruption of EZ, n (%) | 44 (19.5) | 12 (10.9) | 32 (27.6) | 0.002 |
| SRF, n (%) | 41 (18.1) | 24 (21.8) | 17 (14.7) | 0.256 |
| Foveal exudate, n (%) | 17 (7.5) | 6 (5.5) | 11 (9.5) | 0.428 |
| During 12 months | ||||
| Mean (SD) number of injections | 7.3 (3.2) | 6.9 (3.2) | 7.5 (3.2) | 0.183 |
| Receiving additional macular laser photocoagulation, n (%) | 127 (56.2) | 59 (53.6) | 68 (58.6) | 0.494 |
VA visual acuity,SD standard deviation, NPDR non-proliferative diabetic retinopathy,PDR proliferative diabetic retinopathy, PRP panretinal photocoagulation, CSFT central subfield thickness, ERM epiretinal membrane, DRIL disorganization of retinal inner layer, HF hyperreflective foci, IRC intraretinal cyst, ELM external limiting membrane, EZ ellipsoid zone, SRF subretinal fluid
*generalized estimating equation (GEE)